Characterization of a major neutralizing epitope on human papillomavirus type 16 L1

Journal of Virology

Volumn 73, Issue 6, 1999, Pages 4882-4889

  White, Wendy I ^a,c   Wilson, Susan D ^a   Palmer Hill, Frances J ^a   Woods, Robert M ^a   Ghim, Shin Je ^b   Hewitt, Lisa A ^a   Goldman, Daniel M ^a   Burke, Steven J ^a   Jenson, A Bennett ^b   Koenig, Scott ^a   Suzich, Joann A ^a  

^a MEDIMMUNE   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS DNA;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; NONHUMAN; NUCLEOTIDE SEQUENCE; PAPILLOMA VIRUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; VIRUS INFECTION; VIRUS TYPING; WART VIRUS;

EID: 0033033883     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.6.4882-4889.1999     Document Type: Article

References (26)

1. Bosch, F. X., M. M. Manos, N. Munoz, M. Sherman, A. M. Jansen, J. Petro, M. H. Schifman, V. Moreno, R. Kurman, and K. V. Shah. 1995. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J. Natl. Cancer Inst. 87:796-802.
2. Bosch, F. X., S. de Sanjose, S. Castellsague, and N. Munoz. 1997. Geographic and social patterns of cervical cancer incidence, p. 23-33. In E. Franco and J. Monsonego (ed.), New developments in cervical cancer screening and prevention. Blackwell Science, Ltd., Oxford, England.
3. Bradford, M. M. 1976. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
4. Breitburd, F., R. Kirnbauer, N. L. Hubbert, B. Nonnenmacher, C. Trin-Dinh-Desmarquet, G. Orth, J. T. Schiller, and D. R. Lowy. 1995. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. 69:3959-3963.
5. Brown, M., and P. Faulkner. 1977. A plaque assay for nuclear polyhedrosis viruses using a solid overlay. J. Gen. Virol. 36:361-364.
6. Christensen, N. D., J. Dillner, C. Eklund, J. J. Carter, G. C. Wipf, C. A. Reed, N. M. Cladel, and D. A. Galloway. 1996. Surface conformational and linear epitopes on HPV-16 and HPV-18 virus-like particles as defined by monoclonal antibodies. Virology 223:174-184.
7. Finch, J. T., and A. Klug. 1965. The structure of viruses of the papillomapolyoma type. J. Mol. Biol. 13:1-12.
8. Ghim, S.-j. Unpublished observations.
9. Ho, S. N., H. N. Hunt, R. M. Horton, J. K. Pullen, and L. R. Pease. 1989 Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77:51-59.
10. Human Papillomavirus Compendium. 1996. Markov protein alignment of supergroup A genomes II-L1-5. Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, N.Mex.
11. Icenogle, J. P., K. A. Clancy, and S. Y. Lin. 1995. Sequence variation in the capsid protein genes of human papillomavirus type 16 and type 31. Virology 214:664-669.
12. Jansen, K. U., M. Rosolowsky, L. D. Schultz, H. Z. Markus, J. C. Cook, J. J. Donnelly, D. Martinez, R. W. Ellis, and A. R. Shaw. 1995. Vaccination with yeast expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 13: 1509-1514.
13. Karlsson, R., and A. Fält. 1997. Experimental design for the kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors. J. Immunol. Methods 200:121-133.
14. Kirnbauer, R., L. M. Chandrachud, B. W. O'Neil, E. R. Wagner, G. J. Grindlay, A. Armstrong, G. M. McGarvie, J. T. Schiller, D. R. Lowy, and M. S. Campo. 1996. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 219:37-44.
15. Kirnbauer, R., J. Taub, H. Greenstone, R. Roden, M. Dürst, L. Gissman, D. R. Lowy, and J. T. Schiller. 1993. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J. Virol. 67:6929-6936.
16. Li, M., T. P. Cripe, P. A. Estes, M. K. Lyon, R. C. Rose, and R. L. Garcea. 1997. Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly. J. Virol. 71:2988-2995.
17. Ludmerer, S. W., D. Benincasa, and G. E. Mark III. 1996. Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11. J. Virol. 70:4791-4794.
18. McCarthy, M. P., W. I. White, F. Palmer-Hill, S. Koenig, and J. A. Suzich. 1998. Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro. J. Virol. 72:32-41.
19. Roden, R. B. S., A. Armstrong, P. Haderer, N. D. Christensen, N. L. Hubbert, D. R. Lowy, J. T. Schiller, and R. Kirnbauer. 1997. Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J. Virol. 71:6247-6252.
20. Roden, R. B. S., N. L. Hubbert, R. Kirnbauer, N. D. Christensen, D. R. Lowy, and J. T. Schiller. 1996. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J. Virol. 70:3298-3301.
21. Rose, R. C., W. I. White, M. Li, J. A. Suzich, C. Lane, and R. L. Garcea. 1998. Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J. Virol. 72:6151-6154.
22. Sapp, M., C. Fligge, I. Petzak, J. R. Harris, and R. E. Streek. 1998. Papillomavirus assembly requires trimerization of the major capsid protein by disulfides between two highly conserved cysteines. J. Virol. 72:6186-6189.
23. Summers, M. D., and G. E. Smith. 1987. A manual of methods for baculovirus vectors and insect cell culture procedures. Tex. Agric. Exp. Stn. Bull. 1555:26-33.
24. Suzich, J. A., S.-J. Ghim, F. J. Palmer-Hill, W. I. White, J. K. Tamura, J. A. Bell, J. A. Newsome, A. Bennett Jenson, and R. Schlegel. 1995. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. USA 92: 11553-11557.
25. Wang, Z., N. Christensen, J. T. Schiller, and J. Dillner. 1997. A monoclonal antibody against human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J. Gen. Virol. 78:2209-2215.
26. White, W. I., S. D. Wilson, W. Bonnez, R. C. Rose, S. Koenig, and J. A. Suzich. 1998. In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J. Virol. 72:959-964.